Asenapine Tablet
Product Images NDC 69539-059

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Asenapine (NDC 69539-059). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Msn Laboratories Private Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg-flavor (10mg Flavor)

Asenapine sublingual tablets, 10 mg strength, that have a black cherry flavor and come in a pack of 60 unit-dose tablets. The medication contains Phenylalanine 0.17 mg per tablet and may not be suitable for individuals with phenylketonuria. Dosage is indicated as sl, but the remaining text is not available due to errors.*

FDA Label Image

10mg Unflav Carton

FDA Label Image

2 5mg Flavor Carton

Asenapine sublingual tablets are available in unit-dose blisters each containing 2.5mg of asenapine. The tablets are black cherry flavored and contain phenylalanine. They are recommended for sublingual use only and are available by prescription. The storage temperature should be between 15° - 30°C (58°F - 85°F). The medication should be kept out of reach of children. The dosage information is not provided. Manufacturing and distribution information is difficult to read.*

FDA Label Image

5mg Flavor Carton

This is a medication information sheet for Asenapine Sublingual Tablets, 5mg. The tablets are intended for sublingual use and should not be crushed, chewed, or swallowed. The medication contains 0.17mg of phenylalanine per tablet and is flavored with black cherry. The dosage instructions are not available in this text. The medication should be stored at room temperature and kept out of reach of children. This medication is manufactured by a pharmaceutical company named Reckitt Benckiser.*

FDA Label Image

5mg Unflav Carton

FDA Label Image

Structure (Asenapine 01)

FDA Label Image

Figure-1 (Asenapine 02)

FDA Label Image

Figure-2 (Asenapine 03)

FDA Label Image

Figure-3 (Asenapine 04)

This text describes the population of a study or clinical trial. It includes information about different levels of renal and hepatic impairment, smoking status, Japanese ethnicity, and pediatrics. The data presented are based on a comparison to reference groups (normal renal and hepatic function, non-smoker, Caucasian adults). The PK parameters Cmax and AUC are also reported, along with fold change and 90% CI.*

FDA Label Image

Figure-4 (Asenapine 05)

FDA Label Image

Figure-5 (Asenapine 06)

The text appears to be a table representing a clinical trial study for Asenapine Sublingual tablets and Placebo. The table shows the number of patients (2 in each group) and their progress over time (in days) until relapse occurs. The product limit estimators are based on the Kaplan-Meier distribution with censoring at the last contact date.*

FDA Label Image

Step-1 (Asenapine 07)

FDA Label Image

Step-2 (Asenapine 08)

FDA Label Image

Step-3 (Asenapine 09)

FDA Label Image

Step-4 (Asenapine 10)

FDA Label Image

Figure-e (Asenapine 11)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.